Cardiff Oncology Analyst Ratings
Cardiff Oncology Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/11/2023 | 479.71% | HC Wainwright & Co. | $13 → $12 | Maintains | Buy |
| 08/08/2023 | 528.02% | HC Wainwright & Co. | $14 → $13 | Maintains | Buy |
| 05/09/2023 | 576.33% | HC Wainwright & Co. | $15 → $14 | Maintains | Buy |
| 03/29/2023 | 624.64% | HC Wainwright & Co. | → $15 | Reiterates | → Buy |
| 03/07/2023 | 624.64% | HC Wainwright & Co. | $14 → $15 | Maintains | Buy |
| 09/16/2022 | 576.33% | HC Wainwright & Co. | $22 → $14 | Maintains | Buy |
| 09/13/2022 | 141.55% | Piper Sandler | $7 → $5 | Maintains | Overweight |
| 08/29/2022 | 189.86% | Baird | $9 → $6 | Maintains | Outperform |
| 05/09/2022 | 962.8% | HC Wainwright & Co. | $25 → $22 | Maintains | Buy |
| 02/28/2022 | 1107.73% | HC Wainwright & Co. | $26 → $25 | Maintains | Buy |
| 12/08/2021 | 817.87% | Baird | → $19 | Initiates Coverage On | → Outperform |
| 08/10/2021 | 1156.04% | HC Wainwright & Co. | $25 → $26 | Maintains | Buy |
| 05/10/2021 | 1107.73% | HC Wainwright & Co. | $27 → $25 | Maintains | Buy |
| 10/22/2020 | 1204.35% | HC Wainwright & Co. | → $27 | Initiates Coverage On | → Buy |
| 10/08/2020 | 1107.73% | Piper Sandler | → $25 | Initiates Coverage On | → Overweight |
| 09/18/2020 | 576.33% | Maxim Group | $6 → $14 | Maintains | Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023年08月11日 | 479.71% | HC Wainwright公司 | $13→$12 | 维护 | 买 |
| 2023/08/08 | 528.02% | HC Wainwright公司 | $14→$13 | 维护 | 买 |
| 05/09/2023 | 576.33% | HC Wainwright公司 | $15→$14 | 维护 | 买 |
| 03/29/2023 | 624.64% | HC Wainwright公司 | →$15 | 重申 | →购买 |
| 03/07/2023 | 624.64% | HC Wainwright公司 | $14→$15 | 维护 | 买 |
| 09/16/2022 | 576.33% | HC Wainwright公司 | $22→$14 | 维护 | 买 |
| 09/13/2022 | 141.55% | 派珀·桑德勒 | $7→$5 | 维护 | 超重 |
| 2022年08月29日 | 189.86% | 贝尔德 | $9→$6 | 维护 | 跑赢大盘 |
| 05/09/2022 | 962.8% | HC Wainwright公司 | $25→$22 | 维护 | 买 |
| 02/28/2022 | 1107.73% | HC Wainwright公司 | $26→$25 | 维护 | 买 |
| 12/08/2021 | 817.87% | 贝尔德 | →$19 | 开始承保 | →跑赢大盘 |
| 2021/08/10 | 1156.04% | HC Wainwright公司 | $25→$26 | 维护 | 买 |
| 2021/05/10 | 1107.73% | HC Wainwright公司 | $27→$25 | 维护 | 买 |
| 10/22/2020 | 1204.35% | HC Wainwright公司 | →$27 | 开始承保 | →购买 |
| 10/08/2020 | 1107.73% | 派珀·桑德勒 | →$25 | 开始承保 | →超重 |
| 09/18/2020 | 576.33% | Maxim集团 | $6→$14 | 维护 | 买 |
What is the target price for Cardiff Oncology (CRDF)?
卡迪夫肿瘤(CRDF)的目标价格是多少？
The latest price target for Cardiff Oncology (NASDAQ: CRDF) was reported by HC Wainwright & Co. on August 11, 2023. The analyst firm set a price target for $12.00 expecting CRDF to rise to within 12 months (a possible 479.71% upside). 8 analyst firms have reported ratings in the last year.
加的夫肿瘤公司(纳斯达克代码：CRDF)的最新目标价是由HC Wainwright&Co.于2023年8月11日报道的。这家分析公司将目标价定为12美元，预计CRDF将在12个月内上涨(可能上涨479.71%)。去年有8家分析公司公布了评级。
What is the most recent analyst rating for Cardiff Oncology (CRDF)?
加的夫肿瘤学(CRDF)的最新分析师评级是什么？
The latest analyst rating for Cardiff Oncology (NASDAQ: CRDF) was provided by HC Wainwright & Co., and Cardiff Oncology maintained their buy rating.
加的夫肿瘤学公司(纳斯达克代码：CRDF)的最新分析师评级由HC Wainwright&Co.提供，加的夫肿瘤学公司维持买入评级。
When is the next analyst rating going to be posted or updated for Cardiff Oncology (CRDF)?
加的夫肿瘤学(CRDF)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cardiff Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cardiff Oncology was filed on August 11, 2023 so you should expect the next rating to be made available sometime around August 11, 2024.
分析师在进行了广泛的研究后得出股票评级，其中包括查阅公共财务报表，与加的夫肿瘤公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。卡迪夫肿瘤学的上一次评级是在2023年8月11日提交的，所以你应该预计下一次评级将在2024年8月11日左右提供。
Is the Analyst Rating Cardiff Oncology (CRDF) correct?
分析师对加的夫肿瘤学(CRDF)的评级正确吗？
While ratings are subjective and will change, the latest Cardiff Oncology (CRDF) rating was a maintained with a price target of $13.00 to $12.00. The current price Cardiff Oncology (CRDF) is trading at is $2.07, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的加的夫肿瘤学(CRDF)评级保持不变，目标价在13.00美元至12.00美元之间。卡迪夫肿瘤公司目前的交易价格为2.07美元，超出了分析师的预测范围。